- Home
- RPRX vs EXPE Comparison
RPRX vs EXPE Comparison
Compare RPRX & EXPE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | EXPE |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4B | 31.7B |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RPRX | EXPE |
|---|---|---|
| Price | $70.15 | $259.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 37 |
| Target Price | $72.00 | ★ $333.09 |
| AVG Volume (30 Days) | ★ 3.2M | 1.9M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.35% | 0.76% |
| EPS Growth | N/A | ★ 9.61 |
| EPS | 1.03 | ★ 15.43 |
| Revenue | $2,378,193,000.00 | ★ $14,733,000,000.00 |
| Revenue This Year | $49.27 | $11.26 |
| Revenue Next Year | $9.11 | $6.51 |
| P/E Ratio | $67.27 | ★ $16.45 |
| Revenue Growth | 5.06 | ★ 7.61 |
| 52 Week Low | $37.31 | $185.34 |
| 52 Week High | $69.77 | $342.00 |
Technical Indicators
Market Signals| Indicator | RPRX | EXPE |
|---|---|---|
| Relative Strength Index (RSI) | 77.70 | 42.69 |
| Support Level | $55.48 | $254.84 |
| Resistance Level | N/A | $277.79 |
| Average True Range (ATR) | 1.57 | 14.12 |
| MACD | 0.35 | -3.88 |
| Stochastic Oscillator | 95.66 | 16.41 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About EXPE Expedia Group Inc.
Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of 2025 sales), air tickets (3%), rental cars, cruises, in-destination, and other (9%), and advertising revenue (8%). Expedia operates a number of branded travel booking sites, but its three core online travel agency brands are Expedia, Hotels.com, and alternative accommodations brand Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.